ArticleIJID regions2022
SARS-CoV-2 seropositivity and subsequent infection risk: a prospective cohort study.
Article in IJID regions, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Subsequent SARS-CoV-2 Infection in Healthcare Workers: A Retrospective Cohort Study in Iran.Immunity, inflammation and disease · 2026Article
- Article
- SARS-CoV-2-The Role of Natural Immunity: A Narrative Review.Journal of clinical medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This aim of this study was to examine the relationship between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) seropositivity and subsequent infection. Design: A cohort study design was employed. Methods: Stratified random sampling was undertaken to identify individuals aged 10 years and above registered with Qatar's largest primary healthcare provider. A questionnaire was administered, and blood samples were collected and analyzed for immunoglobulin G antibodies against SARS-CoV-2 at baseline. Participants were followed up until March 31, 2021 (a 34-week follow-up period) for vaccination status and a positive polymerase chain reaction (PCR) test for SARS-CoV-2. Results: A total of 2044 individuals participated in the study (97.2% of the planned sample). Of these, 185 (9%) were found to be seropositive at baseline. 450 individuals were vaccinated during the follow-up period - 246 with one dose and 204 with two doses. 86 (4.2%) individuals had a positive PCR test during the follow-up period, of which 80 (3.9%) were seronegative and six (0.3%) were seropositive (five undiluted and one with a titer ≥ 1:8). Conclusions: Overall, the findings suggest that reinfections are uncommon. Antibody concentrations potentially influence the risk of subsequent infection. Therefore, it might not be necessary to subject seropositive individuals to vaccination and the quarantine policies that apply to seronegative individuals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.